Radezolid

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Radezolid
Skeletal formula of radezolid
Clinical data
Routes of
administration
Intravenous infusion, oral
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
Formula C22H23FN6O3
Molar mass 438.455 g/mol
3D model (Jmol)

Radezolid (INN, codenamed RX-1741) is a novel oxazolidinone antibiotic being developed by Melinta Therapeutics, Inc. for the treatment of serious multi-drug–resistant infections. Radezolid has completed two phase-II clinical trials. One of these clinical trials was for uncomplicated skin and skin-structure infections (uSSSI) and the other clinical trial was for community acquired pneumonia (CAP).

References[edit]

External links[edit]